Sandhill Capital Partners LLC Lowers Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Sandhill Capital Partners LLC reduced its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 54.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 178,010 shares of the company's stock after selling 214,551 shares during the quarter. TransMedics Group accounts for 0.9% of Sandhill Capital Partners LLC's portfolio, making the stock its 28th biggest holding. Sandhill Capital Partners LLC owned about 0.53% of TransMedics Group worth $11,099,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Renaissance Group LLC bought a new position in TransMedics Group during the fourth quarter valued at approximately $1,908,000. FIL Ltd raised its stake in TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after buying an additional 218,961 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of TransMedics Group by 2.5% during the 4th quarter. Legal & General Group Plc now owns 95,539 shares of the company's stock valued at $5,957,000 after buying an additional 2,363 shares during the period. Bank of Montreal Can boosted its stake in shares of TransMedics Group by 17.8% in the 4th quarter. Bank of Montreal Can now owns 82,457 shares of the company's stock worth $5,141,000 after buying an additional 12,484 shares during the last quarter. Finally, Sit Investment Associates Inc. bought a new stake in shares of TransMedics Group in the fourth quarter worth $423,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

TransMedics Group Price Performance

Shares of TMDX traded up $4.21 during mid-day trading on Friday, reaching $80.58. The stock had a trading volume of 1,036,118 shares, compared to its average volume of 1,334,231. The firm has a market cap of $2.71 billion, a price-to-earnings ratio of 85.72 and a beta of 2.14. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The business has a fifty day moving average of $70.94 and a 200 day moving average of $81.18. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Finally, JPMorgan Chase & Co. restated a "neutral" rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.